|
PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study. |
|
|
Honoraria - Agenus; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Grunenthal; Immunocore; Incyte; LEO Pharma; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sysmex |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Grunenthal; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech; Sysmex |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche/Genentech |
|
|
Honoraria - Bristol-Myers Squibb; Merck; Roche |
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; MERCK; Novartis; Pierre Fabre; Roche/Genentech |
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche/Genentech |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche |
Speakers' Bureau - Novartis |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Immunocore; Ipsen; MSD; Novartis; Pfizer; Pierre Fabre |
Speakers' Bureau - Bristol-Myers Squibb; Novartis |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD |
|
|
Stock and Other Ownership Interests - Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company |
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck; Novartis |
|
|
Consulting or Advisory Role - Genentech/Roche; GlaxoSmithKline; Novartis; Sanofi; Vaccinex |
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
Research Funding - Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Serono; Novartis; Roche |